C. Ruiz-mesa, J. M. Goldberg, A. J. Coronado-munoz, S. N. Dumont, and J. C. Trent, Rhabdomyosarcoma in Adults: New Perspectives on Therapy, vol.16, 2015.

O. Oberlin, A. Rey, J. Sanchez-de, and . Toledo, Randomized comparison of intensified six-drug versus standard three-drug chemotherapy for high-risk nonmetastatic rhabdomyosarcoma and other chemotherapy-sensitive childhood soft tissue sarcomas: long-term results from the International Society of Pediatric Oncology MMT95 study, Journal of Clinical Oncology, vol.30, issue.20, pp.2457-2465, 2012.

R. Bagatell, R. Norris, and A. M. Ingle, Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a children's oncology group study, Pediatric Blood and Cancer, vol.61, issue.5, pp.833-839, 2014.

E. Beutler, T. Gelbart, and A. Demina, Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism, Proceedings of the National Academy of Sciences of the United States of America, vol.95, pp.8170-8174, 1998.

K. Matsui, Y. Maruo, H. Sato, and Y. Takeuchi, Combined effect of regulatory polymorphisms on transcription of UGT1A1 as a cause of Gilbert syndrome, BMC Gastroenterology, vol.10, issue.57, 2010.

L. Iyer, C. D. King, and P. F. Whitington, Genetic predisposition to the metabolism of irinotecan (CPT-11): role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes, The Journal of Clinical Investigation, vol.101, issue.4, pp.847-854, 1998.

A. Kadakol, S. S. Ghosh, B. S. Sappal, G. Sharma, J. R. Chowdhury et al., Genetic lesions of bilirubin uridine-diphosphoglucuronate glucuronosyltransferase (UGT1A1) causing Crigler-Najjar and Gilbert syndromes: Correlation of genotype to phenotype, Human Mutation, vol.16, issue.4, pp.297-306, 2000.

F. Innocenti, D. L. Kroetz, and E. Schuetz, Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics, Journal of Clinical Oncology, vol.27, issue.16, pp.2604-2614, 2009.

M. Del-re, C. Cremolini, and F. Loupakis, DPYD c.1905 + 1G > A and c.2846A > T and UGT1A1 * 28 allelic variants as predictors of toxicity: pharmacogenetic translational analysis from the Phase III TRIBE study in metastatic colorectal cancer, Journal of Clinical Oncology, pp.33-3532, 2015.

E. Marcuello, D. Páez, and L. Paré, A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer, British Journal of Cancer, vol.105, issue.1, pp.53-57, 2011.

E. V. Cutsem, A. Cervantes, and R. Adam, ESMO consensus guidelines for the management of patients with metastatic colorectal cancer, Annals of Oncology, vol.27, pp.1386-1422, 2016.

. Camptosar, , 2017.

S. Quaranta and F. Thomas, Pharmacogenetics of anti-cancer drugs: state of the art and implementation-recommendations of the French National Network of Pharmacogenetics, Therapie, vol.72, issue.2, pp.205-215, 2017.

R. Roncato, E. Cecchin, and M. Montico, Cost Evaluation of Irinotecan-Related Toxicities Associated With the UGT1A1 * 28 Patient Genotype, Clinical Pharmacology and Therapeutics, 2017.